| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000014338 |
| Receipt No. | R000016635 |
| Official scientific title of the study | Clinical study to examine the efficacy of the intravitreal injection of anti-VEGF antibody (Avastin) for intraocular neovascular disease and macular edema |
| Date of disclosure of the study information | 2014/06/25 |
| Last modified on | 2017/01/29 (Ver. 4) |
| Basic information | ||
| Official scientific title of the study | Clinical study to examine the efficacy of the intravitreal injection of anti-VEGF antibody (Avastin) for intraocular neovascular disease and macular edema | |
| Title of the study (Brief title) | Clinical study to examine the efficacy of the intravitreal injection of anti-VEGF antibody (Avastin) | |
| Region |
|
|
| Condition | ||
| Condition | Ophthalmic neovascular disease
Diabetic retinopathy Retinal vein occlusion |
|
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | A purpose of this study is to examine the efficacy of intraocular bevacizumab for ophthalmic neovascular disease and macular edema |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Ocular fundus
|
| Key secondary outcomes | Visual acuity
Optical coherence tomography Fluorescein angiography Improvement of visual field Improvement of intraocular pressure |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | intravitreal bevacizumab | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1) Ophthalmic neovasular disease
2) Diabetic retinopathy 3) Retinal vein occlusion 4) Patient 20 years or older at the time of the agreement acquisition 5) The patient that understands this study enough and the agreement in the document by the free will was provided after having received enough explanation |
|||
| Key exclusion criteria | 1) The patient who has difficulty in observation of the fundus for high cataract, corneal clouding
2) Patient younger than 20 years 3) The patient who received other study medication or other clinical experimental medicine within three months before this medication start 4) In addition, the patient who judged an examination responsibility (allotment) doctor to be inappropriate as a subject |
|||
| Target sample size | 3000 | |||
| Research contact person | |
| Name of lead principal investigator | Shuichi Yamamoto |
| Organization | Chiba University Graduate School of Medicine |
| Division name | Department of Ophthalmology and Visual Science |
| Address | 1-8-1, Inohana, Chuo-ku, Chiba-City, Chiba, Japan |
| TEL | 043-222-7171 |
| shuyama@faculty.chiba-u.jp | |
| Public contact | |
| Name of contact person | Tomoaki Tatsumi |
| Organization | Chiba University Graduate School of Medicine |
| Division name | Department of Ophthalmology and Visual Science |
| Address | 1-8-1, Inohana, Chuo-ku, Chiba-City, Chiba, Japan |
| TEL | 043-222-7171 |
| Homepage URL | |
| newyear98mt@yahoo.co.jp | |
| Sponsor | |
| Institute | Department of Ophthalmology and Visual Science, Chiba University Graduate School of Medicine |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Chiba University Hospital |
| Organization | |
| Division | |
| Category of Funding Organization | |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000016635 |